Clinical trial
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic…
NCT00424177 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00424177 |
|---|---|
| Title | Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) |
| Official title | An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopaenic, Idiopathic |
| Intervention type | Drug |
| Interventions | eltrombopag |
| Enrollment | 66 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Jul 30, 2013 |
| Countries | Germany, Russia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: